Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

33.2K
Overview
33.2K
Vaccinations01:51

Vaccinations

52.2K
Overview
52.2K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of cross-stage, cross-species malaria CD8<sup>+</sup> T cell antigens.

Nature·2026
Same author

Bivalent virus-like particles expressing SPECT1 and CSP trigger pre-erythrocytic malaria immunity and protect against transgenic <i>Plasmodium falciparum</i> sporozoite challenge in mice.

Frontiers in immunology·2026
Same author

Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study.

Vaccine·2026
Same author

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.

Wellcome open research·2026
Same author

African-specific genetic loci determine iron status and risk of severe malaria and bacteremia in African children.

Nature communications·2026
Same author

Immunogenicity and safety of an inactivated split-virion influenza vaccine in individuals 6 months of age and older in India.

Human vaccines & immunotherapeutics·2026

Related Experiment Video

Updated: Feb 25, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K

Vaccines against Ebola virus.

Navin Venkatraman1, Daniel Silman1, Pedro M Folegatti1

  • 1Jenner Institute, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.

Vaccine
|August 7, 2017
PubMed
Summary

The 2014 Ebola outbreak accelerated vaccine development, leading to promising candidate vaccines. Further research is needed to ensure licensed vaccines are available for future Ebola virus disease outbreaks.

Keywords:
EbolaOutbreakRing vaccinationVaccineWest Africa

More Related Videos

Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

33.7K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K

Related Experiment Videos

Last Updated: Feb 25, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K
Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

33.7K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K

Area of Science:

  • Virology
  • Vaccinology
  • Epidemiology

Background:

  • The 2014 Ebola virus disease outbreak underscored the critical need for effective vaccines.
  • Limited global impetus existed for Ebola vaccine development prior to 2014, despite the virus's 1976 discovery.

Purpose of the Study:

  • To review the history and progress of Ebola vaccine development.
  • To discuss lessons learned and future challenges in ensuring vaccine availability for future outbreaks.

Main Methods:

  • Accelerated clinical development of candidate vaccines through global collaboration.
  • Initiation of a landmark efficacy trial for an rVSV-vectored vaccine.
  • Acquisition of safety and immunogenicity data in diverse populations.

Main Results:

  • Demonstrated high-level efficacy of an rVSV-vectored vaccine in an outbreak setting using ring vaccination.
  • Generated substantial safety and immunogenicity data for multiple candidate vaccines.

Conclusions:

  • The 2014 outbreak significantly advanced Ebola vaccine development, yielding promising candidates.
  • Ensuring a licensed, deployable vaccine for Zaire and Sudan strains remains a priority.
  • Further research is required on protection durability, immunological correlates, and deployment strategies.